Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Job title: Professor
Professor Keith AA Fox is Duke of Edinburgh Professor of Cardiology at the University of Edinburgh. Previous posts included Assistant Professor of Internal Medicine and Cardiology at Washington University School of Medicine, St Louis, USA; Senior Lecturer in Cardiology and Honorary Consultant Cardiologist at the University of Wales College of Medicine, Cardiff; Head of Division of Medical and… View more
REDUCE-IT: CV Outcomes With Icosapent Ethyl by Baseline LDL-C
Author(s): Deepak L Bhatt Added: 1 year ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants… View more

Prevention & Chronic Conditions
TCT 2025: SELUTION DeNovo: 1-Year Results Comparing Sirolimus Balloon vs DES in PCI
Author(s): Christian Spaulding Added: 6 months ago
TCT 2025 — Prof Christian M Spaulding (European Hospital Georges Pompidou & INSERM U 970, FR), principal investigator of the SELUTION DeNovo trial (M.A. Med Alliance S.A.; NCT04859985), joins us to share the one year results.This international, multicentre randomised trial enrolled over 3,300 patients at 50 sites across Europe and Asia to compare a sirolimus-eluting balloon (SEB) plus provisional… View more

Intervention
Sotiris Antoniou, Consultant Pharmacist
Research Area(s) / Expertise:

Anticoagulation

 Job title: Consultant Pharmacist & Lead Cardiovascular Pharmacist
Mr Sotiris Antoniou is Consultant Pharmacist at Barts Heart Centre, part of Barts Health NHS Trust. Combined with his role as Lead Cardiovascular Pharmacist for UCL Partners supports medicines optimisation across the health economy to optimise patient outcomes and address unmet local needs. He is an independent prescriber and is currently chair of the cardiac committee for United Kingdom Clinical… View more
Drug-coated Balloon Angioplasty in Sri Lanka
Author(s): Yanushka Herath , Judy Ranaweera , Thisal Semina , et al Added: 5 months ago

Intervention

Prevention & Chronic Conditions
Ez-PAVE: Lower LDL-C Target Reduces CV Events
Added: 1 month ago Source:  Radcliffe CVRM
Recent US guidelines have controversially recommended lowering the low-density lipoprotein cholesterol (LDL-C) target to <55 mg/dL for patients with established atherosclerotic cardiovascular disease (ASCVD).¹˒² The Ez-PAVE trial is the first randomised study to directly compare this intensive target with a conventional target of <70 mg/dL. The findings were published in The New England… View more

Cardiovascular Kidney Metabolic

Demographic
Added: 1 month ago Source:  Interventional Cardiology Review Journal
Long-term follow-up from the FAMOUS-NSTEMI trial suggests that a fractional flow reserve-guided strategy for managing patients with non-ST-segment elevation myocardial infarction (NSTEMI) does not reduce adverse cardiovascular outcomes compared to standard angiography-guided care.¹MethodologyFAMOUS-NSTEMI was a prospective, randomised, controlled trial that enrolled 350 patients with NSTEMI… View more

Intervention

MI/ACS
A Michael Lincoff
Research Area(s) / Expertise:
Dr A. Michael Lincoff, MD, assumes the role of Vice Chairman within the Robert and Suzanne Tomsich Department of Cardiovascular Medicine, acting as an interventional cardiologist at the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic.With a purview extending beyond clinical practice, Dr Lincoff spearheads clinical research endeavours throughout the… View more
Plaque Burden on CCTA Predicts MACE in Early CAD
Added: 2 months ago Source:  Radcliffe Vascular
A post hoc analysis of the PROMISE trial has found that quantitative coronary plaque measures derived from coronary computed tomographic angiography (CCTA) can independently predict major adverse cardiovascular events (MACE) in symptomatic patients without a known history of coronary artery disease (CAD).¹ The findings suggest that total plaque burden and noncalcified plaque burden may enhance… View more

Imaging & Diagnostics

Prevention & Chronic Conditions
Sergey Kozhukhov
Research Area(s) / Expertise:

Cardio-oncology

Heart Failure

MI/ACS

Atrial Fibrillation

 Job title: Director of the Cardio-Oncology Center and Head of Clinical Pharmacology and Cardio-Oncology Department
Dr Sergey Kozhukhov is the founder and Director of the Cardio-Oncology Center and Head of Clinical Pharmacology and Cardio-Oncology Department at Strazhesko Institute of Cardiology, Kyiv, UA.His practice focuses on diagnosing and treating cardiovascular complications in patients with active cancer and his research focuses on studying early biomarkers of myocardial damage. Dr Kozhukhov has… View more